PHVS

Pharvaris N.V. is a biopharmaceutical company that develops oral treatments for hereditary angioedema, a rare genetic condition that causes sudden swelling attacks. The company creates pills that patients can take to prevent or treat these swelling episodes, aiming to provide a more convenient alternative to current injectable therapies. Pharvaris makes money by advancing its drug candidates through clinical trials and, if approved, plans to sell these medicines to patients through healthcare providers.